CEO Darren Lurie updates Proactive on the development of its new clinical system for oral cancer screening and surgery, on going clinical trials and new China distributor

Optiscan Imaging Limited (ASX:OIL) chief executive officer and chairman Darren Lurie provides an update on the development of Optiscan’s new applications in cancer screening and visual aid in cancer surgery. Optiscan’s technology is used to enhance screening for potential cancer and a number of key trials are underway or expected to commence shortly in US and Australian hospitals. The CEO also updates on the appointment of a new distributor in China, following a review of its China market strategy and the adoption of a multi-distributor model.

Watch the Youtube Video here